Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics that enable clinicians to detect scientifically validated biomarkers and optimally treat GI diseases, including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS.
Gemelli Biotech has support and advisement from healthcare professionals with clinical and research focus on various areas of gastroenterology and hepatology, including motility, function, and bowel and intestinal disorders.
Established in 2018 by healthcare practitioners with expertise in the gastrointestinal system, Gemelli Biotechis headquartered in Raleigh, North Carolina.
Gemelli Biotech is partnered with the Medically Associated Science and Technology (MAST) program at Cedars Sinai (Los Angeles) as a patient-focused laboratory that is able to meet the needs for precision diagnostics for personalized management of gastrointestinal functioning.
Gemelli Biotech offers two diagnostic tests that provide information on the microbes residing within the gastrointestinal system: the IBS-smart test, which is a blood test assessing for particular antibody levels indicative of IBS; and the trio-smart test, which is a breath test to assess levels of hydrogen, methane, and hydrogen sulfide for abnormalities.
The results from these tests can facilitate diagnosing and managing specific gastrointestinal issues such as irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO), and excess hydrogen sulfide.
They are guided by a team of international doctors on their scientific advisory board.
The vision of Gemelli Biotech is to be “a lab that operates mindfully, treats patients compassionately, and empowers clinicians to find answers in more efficient and effective ways.”
In pursuit of that vision, Gemelli Biotech has set a mission to leverage leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.
Gemelli Biotech offers specialized diagnostic tools to aid providers in understanding the pathophysiology and guiding management of patients with complex and chronic digestive complaints.
The ibs-smart Diagnostic Test represents a significant advancement in the diagnosis of irritable bowel syndrome with a diarrheal component (IBS-D and IBS-M).
This test specifically measures two antibodies, anti-CdtB and anti-vinculin, which have been validated in a large-scale study at Cedars-Sinai as specific biomarkers for IBS. These antibodies are typically elevated following gastroenteritis, suggesting that the IBS in these patients was triggered by an infectious event.
The presence of anti-CdtB and anti-vinculin indicates an immune response initially aimed at Cytolethal Distending Toxin B (CdtB) produced during bacterial food poisoning. Due to molecular mimicry, the immune system also produces anti-vinculin, which mistakenly targets and damages vital proteins in the gut, leading to nerve damage and dysmotility characteristic of IBS-D or IBS-M.
Symptoms resulting from this condition include abdominal pain, bloating, and diarrhea, providing a clear linkage from food poisoning to IBS.
This test offers a critical diagnostic tool by confirming the organic and infectious origins of IBS, thereby facilitating targeted management of the condition.
The ibs-smart blood test utilizes an at-home blood collection kit facilitated by the Tasso+ device.
The trio-smart SIBO Breath Test is a sophisticated diagnostic tool designed to detect small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO), and excess hydrogen sulfide production, which are often the culprits behind symptoms like bloating, gas, abdominal pain, and altered bowel movements.
Conducted through an easy at-home sample collection and analyzed in a CLIA-certified lab, the Trio-Smart test offers a cost-effective and sensitive method to detect bacterial overgrowth and carbohydrate malabsorption.
This allows healthcare providers to develop customized treatment plans based on specific gastrointestinal disruptions, aiding in the effective management and improvement of patient well-being.
Gemelli Biotech also offers a suite of malabsorption tests aimed at diagnosing problems related to the digestion of specific sugars. These include:
trio-smart Lactose Malabsorption Test
A positive finding on the trio-smart Lactose Malabsorption Test suggests lactose malabsorption in the small intestine, potentially causing symptoms like bloating, abdominal pain, diarrhea, and flatulence.
This condition, often due to a deficiency of the enzyme lactase, impedes the body's ability to digest lactose.
The test is a non-invasive, efficient way to diagnose lactose malabsorption, enabling healthcare providers to guide dietary adjustments and treatment. This may include reducing lactose intake or using lactase supplements to aid digestion.
Additionally, since lactose malabsorption can lead to bacterial overgrowth, this breath test can identify underlying causes of gastrointestinal discomfort and support tailoring specific management strategies to improve patients' quality of life.
trio-smart Fructose Malabsorption Test
The trio-smart Fructose Malabsorption Test can help diagnose fructose malabsorption, which can lead to symptoms like bloating, gas, and diarrhea.
Fructose is commonly used in breath testing to diagnose fructose malabsorption, a condition that can lead to symptoms like bloating, gas, and diarrhea. A positive result on a Trio-Smart breath test using fructose as a substrate suggests that fructose may not be adequately absorbed in the small intestine.
This malabsorption occurs when there are deficiencies in the transporters or enzymes needed to process fructose, allowing unabsorbed fructose to ferment in the colon and produce gasses detected during the test.
trio-smart Sucrose Malabsorption Test
The trio-smart Sucrose Malabsorption Test aids in the diagnosis of digestive issues related to sucrose digestion.
A positive result on the Trio-Smart breath test using sucrose as a substrate suggests an impaired ability to break down sucrose in the small intestine, potentially leading to symptoms like bloating, abdominal pain, diarrhea, and flatulence.
This test assesses the functionality of the enzyme sucrase, which is responsible for splitting sucrose into fructose and glucose at the intestinal lining. Identifying a deficiency in sucrase activity through this non-invasive and efficient breath test enables healthcare providers to offer precise dietary adjustments and treatment options.
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS.
.jpg)
